Moderator(s):
Dominick J. Angiolillo, Duk-Woo Park
Panelist(s): Sripal Bangalore, David Joel Cohen, Byeong-Keuk Kim, Tullio Palmerini, Kyung Woo Park, Pieter Smits, Hiroyoshi Yokoi
Panelist(s): Sripal Bangalore, David Joel Cohen, Byeong-Keuk Kim, Tullio Palmerini, Kyung Woo Park, Pieter Smits, Hiroyoshi Yokoi
Antiplatelet Issues
- Standardizing the Language on Bleeding and Ischemic Risks: Insights on ARC, BARC, VARC, and Others
Pieter Smits - Escalation Strategy of Antithrombotic Therapy: Why, in Whom, and How?
Tullio Palmerini - De-Escalation Strategy of Antithrombotic Therapy: Why, in Whom, and How?
Sripal Bangalore - Escalation and De-Escalation Strategy for CHIP-PCI Patients: The TAILORED-CHIP Trial
Duk-Woo Park - Panel Discussion l
Anticoagulation Issues
- Don't Forget About Dual Pathway Inhibition: When DOAC Should Not Be Standard Treatment
Dominick J. Angiolillo - Factor XI Inhibitors in Availalbe RCTs: A Meta-analysis and Future Perspectives
Roxana Mehran - Long-term DOAC Management of AF and Stable CAD: Expectation on the EPIC-CAD Trial After the AFIRE Trial
Gi-Byoung Nam - Panel Discussion ll